Johnson & Johnson Stops Mid-Stage Eczema Drug Trial
TL;DR
Johnson & Johnson has discontinued its mid-stage trial of the experimental eczema drug JNJ-5939 after it failed to meet efficacy goals, but remains committed to developing other treatments for atopic dermatitis.
Topics:businesshealth#atopic-dermatitis#clinical-trial#drug-development#eczema#health#johnson-and-johnson
Want the full story? Read the original reporting
Read on CNBC